查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1879270

猴痘治療市場－全球產業規模、佔有率、趨勢、機會和預測，按治療方法（天花疫苗、抗病毒藥物、牛痘免疫球蛋白）、最終用戶、地區和競爭格局分類，2020-2030年預測

Monkeypox Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin ), By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球猴痘治療藥物市場規模為8,700萬美元，預計2030年將以9.01%的複合年成長率成長至1.4599億美元。猴痘治療藥物涵蓋多種藥物介入措施，包括抗病毒藥物和疫苗，主要用於預防和治療猴痘病毒感染。這些介入措施針對的是一種以類似天花症狀為特徵的人畜共通傳染病。全球猴痘治療藥物市場成長的主要促進因素是各地猴痘疫情的不斷增加。此外，各國政府優先考慮公共衛生防範的舉措，包括策略性儲備抗病毒藥物和疫苗，也進一步推動了市場成長。

市場概覽
預測期 2026-2030
2024年市場規模 8700萬美元
2030年市場規模 1.4599億美元
2025-2030年複合年成長率 9.01%
成長最快的細分市場 天花疫苗
最大的市場 北美洲

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球猴痘治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依治療方法（天花疫苗、抗病毒藥物、牛痘免疫球蛋白（VIG））
    • 按最終使用者（醫院、專科診所、門診手術中心、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美猴痘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲猴痘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區猴痘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲猴痘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美猴痘治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最新進展

第13章：全球猴痘治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Chimerix Inc.
  • SIGA Technologies, Inc.
  • Emergent BioSolutions Inc.
  • Bavarian Nordic A/S
  • Hetero Drugs Limited
  • Mylan NV
  • Piramal Enterprises Limited
  • Olon SpA
  • Teva Pharmaceutical Industries Limited
  • CIDIC Company Limited

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 10581

The Global Monkeypox Therapeutics Market, valued at USD 87.00 Million in 2024, is projected to experience a CAGR of 9.01% to reach USD 145.99 Million by 2030. Monkeypox therapeutics encompass pharmaceutical interventions, including antiviral drugs and vaccines, primarily utilized for the prevention and treatment of monkeypox virus infections. These interventions address the zoonotic disease characterized by smallpox-like symptoms. The global market for these therapeutics is driven by the increasing incidence of monkeypox outbreaks in various regions. Further impetus stems from governmental initiatives prioritizing public health preparedness, which includes the strategic stockpiling of antiviral treatments and vaccines.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 87.00 Million
Market Size 2030USD 145.99 Million
CAGR 2025-20309.01%
Fastest Growing SegmentSmallpox Vaccine
Largest MarketNorth America

Key Market Drivers

The increasing global incidence of monkeypox outbreaks profoundly influences the therapeutics market by creating an urgent and sustained demand for effective treatments and preventative measures. Each new surge in cases directly translates into a heightened need for antiviral drugs and vaccines to manage symptoms, prevent severe disease, and curb transmission. According to the Pan American Health Organization/WHO, in October 2024, an Epidemiological Update reported 109,699 confirmed cases of mpox globally between January 2022 and September 30, 2024, further indicating a monthly increase of 8% in new cases in September 2024 compared to August, underscoring the ongoing spread of the virus and the persistent threat it poses to public health. This rising incidence drives pharmaceutical companies to allocate resources towards research and development, aiming to innovate and expand their portfolio of monkeypox therapeutics.

Key Market Challenges

The limited availability of specifically approved therapeutic agents for monkeypox presents a substantial challenge to the growth of the Global Monkeypox Therapeutics Market. Current treatment protocols frequently depend on drugs originally developed for smallpox, which may not consistently prove optimal or widely accessible for monkeypox virus infections. This reliance creates a significant barrier to the rapid and widespread deployment of tailored interventions, particularly when considering evolving viral clades and diverse geographical spread.

Key Market Trends

The global monkeypox therapeutics market is experiencing significant evolution, driven by shifts in drug development and preventative strategies. One prominent trend is the **Evolution Towards Oral Antiviral Therapeutic Options**. This movement is crucial for improving patient access, adherence, and facilitating outpatient care, thereby easing the burden on healthcare infrastructure. Oral formulations offer a more convenient alternative to intravenous treatments, which can be critical during outbreaks. For example, NanoViricides, Inc. announced in July 2025 the near-finalization of its adaptive Phase II clinical trial protocol for NV-387, a novel oral antiviral designed to treat monkeypox virus infections, highlighting the ongoing efforts to develop user-friendly treatment options. This aligns with a broader pharmaceutical industry trend where oral drug development remains a priority due to its patient-centric benefits.

Key Market Players

  • Chimerix Inc.
  • SIGA Technologies, Inc.
  • Emergent BioSolutions Inc.
  • Bavarian Nordic A/S
  • Hetero Drugs Limited
  • Mylan N.V.
  • Piramal Enterprises Limited
  • Olon S.p.A.
  • Teva Pharmaceutical Industries Limited
  • CIDIC Company Limited

Report Scope:

In this report, the Global Monkeypox Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Monkeypox Therapeutics Market, By Treatment:

  • Smallpox Vaccine
  • Antivirals
  • Vaccinia Immune Globulin (VIG)

Monkeypox Therapeutics Market, By End User:

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others

Monkeypox Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Monkeypox Therapeutics Market.

Available Customizations:

Global Monkeypox Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Monkeypox Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin (VIG))
    • 5.2.2. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Monkeypox Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Monkeypox Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Monkeypox Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Monkeypox Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment
        • 6.3.3.2.2. By End User

7. Europe Monkeypox Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Monkeypox Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment
        • 7.3.1.2.2. By End User
    • 7.3.2. France Monkeypox Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Monkeypox Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Monkeypox Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Monkeypox Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment
        • 7.3.5.2.2. By End User

8. Asia Pacific Monkeypox Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Monkeypox Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment
        • 8.3.1.2.2. By End User
    • 8.3.2. India Monkeypox Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Monkeypox Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Monkeypox Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Monkeypox Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment
        • 8.3.5.2.2. By End User

9. Middle East & Africa Monkeypox Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Monkeypox Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Monkeypox Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Monkeypox Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment
        • 9.3.3.2.2. By End User

10. South America Monkeypox Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Monkeypox Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Monkeypox Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Monkeypox Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Monkeypox Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Chimerix Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. SIGA Technologies, Inc.
  • 15.3. Emergent BioSolutions Inc.
  • 15.4. Bavarian Nordic A/S
  • 15.5. Hetero Drugs Limited
  • 15.6. Mylan N.V.
  • 15.7. Piramal Enterprises Limited
  • 15.8. Olon S.p.A.
  • 15.9. Teva Pharmaceutical Industries Limited
  • 15.10. CIDIC Company Limited

16. Strategic Recommendations

17. About Us & Disclaimer